Loading...
•
Dec 31, 2025
Insmed Q4 2025 Earnings Report
Insmed reported strong fourth-quarter 2025 revenue growth driven by the U.S. launch of BRINSUPRI, while posting a wider net loss due to increased R&D and SG&A expenses.
Key Takeaways
Insmed generated 263843000 in Q4 2025 revenue, led by 144600000 from BRINSUPRI and 119200000 from ARIKAYCE. Operating expenses increased significantly, resulting in a net loss of 328485000 for the quarter.
Total Q4 revenue reached 263843000, up significantly year over year.
BRINSUPRI generated 144600000 in its first full quarter following U.S. launch.
ARIKAYCE delivered 119200000 in Q4 revenue, up 14% year over year.
R&D and SG&A expenses increased to support pipeline expansion and commercialization.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company expects full-year 2026 BRINSUPRI revenue of at least 1000000000 and ARIKAYCE revenue between 450000000 and 470000000, while continuing heavy investment in commercialization and pipeline expansion.
Positive Outlook
- BRINSUPRI expected to generate at least 1000000000 in 2026 revenue.
- ARIKAYCE 2026 revenue guidance reaffirmed at 450000000 to 470000000.
- Strong commercial momentum following BRINSUPRI launch.
- Cash position of approximately 1400000000 supports operations.
- Multiple Phase 3 and pipeline programs advancing.
Challenges Ahead
- Net loss widened year over year.
- R&D expenses increased significantly.
- SG&A expenses rose due to commercialization efforts.
- High operating loss driven by pipeline and launch investments.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...